Validation of the Menopause Rating Scale for Hormone Therapy
Author Information
Author(s): Jürgen Dinger, Thomas Zimmermann, Lothar AJ Heinemann, Diana Stoehr
Primary Institution: Center for Epidemiology & Health Research Berlin
Hypothesis
The individual MRS interviews performed by the physician biased the results towards over-estimation of the treatment effects.
Conclusion
The study confirmed that the MRS scale can effectively measure treatment effects on quality of life, but biases may arise from different application methods.
Supporting Evidence
- The MRS scale was validated as an outcome measure for hormone therapy.
- The study found that the self-administered MRS scale showed less improvement compared to the interview-based version.
- Sensitivity and specificity of the MRS scale were lower in the new study compared to the previous one.
Takeaway
This study shows that a questionnaire about menopause symptoms works better when women fill it out themselves rather than when a doctor asks them.
Methodology
An open post-marketing study analyzing pre- and post-treatment data from a self-administered version of the MRS scale.
Potential Biases
Potential bias from the method of data collection, as physician interviews may influence patient responses.
Limitations
The study design does not allow differentiation between true treatment effects and placebo effects.
Participant Demographics
Mean age was 53.9 years, with 20% under 50, 66% between 50-60, and 14% over 60.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website